Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | FOS | P01100 | 2/20 | 0.40 |
| ▸ | JUN | P05412 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192118 | 0.85 | ALDH1A1 (0.57) | KDM4EMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL5265309 | 0.84 | ALDH1A1 (0.51) | KDM4EMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL29207870 | 0.82 | SYK (0.41) | KDM4EALDH1A1LMNATGFBR1SYK | |
| SCHEMBL30775503 | 0.82 | SYK (0.41) | KDM4EALDH1A1LMNATGFBR1SYK | |
| SCHEMBL22440654 | 0.81 | P2RX7 (0.45) | KDM4EALDH1A1LMNATGFBR1GAA | |
| SCHEMBL29827383 | 0.80 | KDM4E (0.48) | KDM4EMAPTALDH1A1SMN1; SMN2SYK | |
| SCHEMBL28944494 | 0.80 | KDM4E (0.48) | KDM4EMAPTALDH1A1SMN1; SMN2SYK | |
| SCHEMBL1498542 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1LMNAATMTSHR | |
| SCHEMBL31697314 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1LMNAATMTSHR | |
| SCHEMBL13853223 | 0.78 | CYP1A2 (0.50) | KDM4EMAPTALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360117-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| CN-113710276-B | Benzodiazepine derivatives as RSV inhibitors | 英安塔制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11254664-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254664-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3941525-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113710276-A | Benzodiazepine derivatives as RSV inhibitors | 英安塔制药有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20200299286-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20200299286-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2020-09-24 | — | — | US | disclosed |
| WO-2020190935-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254664-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885MAPT 2157/4885ALDH1A1 621/4885 |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885MAPT 2157/4885ALDH1A1 621/4885 |
| US-20240360117-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885MAPT 2157/4885ALDH1A1 621/4885 |
| US-20200299286-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885MAPT 2157/4885ALDH1A1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.